Zepp Health (NYSE:ZEPP) Stock Rating Lowered by Wall Street Zen

Zepp Health (NYSE:ZEPP) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

Separately, Fundamental Research set a $56.28 price target on Zepp Health and gave the company a “buy” rating in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Zepp Health presently has a consensus rating of “Hold” and an average price target of $56.28.

Zepp Health Stock Up 0.3%

Shares of NYSE:ZEPP opened at $4.92 on Friday. The firm has a 50 day simple moving average of $5.88 and a 200 day simple moving average of $13.72. Zepp Health has a 52 week low of $3.85 and a 52 week high of $61.85. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.67 and a current ratio of 0.88. The company has a market cap of $72.15 million, a PE ratio of -1.95 and a beta of 1.83.

Insider Transactions at Zepp Health

In other Zepp Health news, CFO Cheng Deng sold 9,836 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $4.61, for a total transaction of $45,343.96. Following the transaction, the chief financial officer directly owned 114,539 shares of the company’s stock, valued at $528,024.79. This represents a 7.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 36.00% of the company’s stock.

Institutional Trading of Zepp Health

Large investors have recently made changes to their positions in the stock. Monolith Management Ltd bought a new position in shares of Zepp Health in the 4th quarter valued at approximately $3,601,000. Lighthouse Investment Partners LLC acquired a new stake in Zepp Health in the 3rd quarter worth approximately $2,070,000. State Street Corp bought a new stake in Zepp Health during the fourth quarter worth approximately $3,421,000. Balyasny Asset Management L.P. boosted its position in Zepp Health by 46.9% during the fourth quarter. Balyasny Asset Management L.P. now owns 202,775 shares of the company’s stock worth $5,463,000 after purchasing an additional 64,692 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Zepp Health by 17.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 295,967 shares of the company’s stock valued at $7,974,000 after purchasing an additional 44,619 shares during the last quarter. Institutional investors own 52.61% of the company’s stock.

Zepp Health Company Profile

Zepp Health Corp is a technology company specializing in the design, development and sale of smart wearable devices and health management solutions. Through its flagship Amazfit brand and the Zepp software ecosystem, the company offers a range of products—including smartwatches, fitness bands, smart scales and health-oriented mobile applications—designed to track key biometric data such as heart rate, sleep patterns, blood oxygen levels and activity metrics. Zepp Health’s integrated platform enables users to monitor wellness and fitness goals while leveraging cloud-based analytics for personalized insights.

At the core of Zepp Health’s offering is its Zepp cloud platform, which aggregates and analyzes data collected from its hardware lineup.